Screening hysteroscopy in subfertile women and women undergoing assisted reproduction

被引:29
|
作者
Kamath, Mohan S. [1 ]
Bosteels, Jan [2 ]
D'Hooghe, Thomas M. [3 ]
Seshadri, Srividya [4 ]
Weyers, Steven [5 ]
Mol, Ben Willem J. [6 ]
Broekmans, Frank J. [7 ]
Sunkara, Sesh Kamal [8 ]
机构
[1] Christian Med Coll & Hosp, Dept Reprod Med, Ida Scudder Rd, Vellore 632004, Tamil Nadu, India
[2] Cochrane Belgium, Acad Ctr Gen Practice, Leuven, Belgium
[3] Leuven Univ, Univ Hosp Gasthuisberg, Fertil Ctr, Leuven, Belgium
[4] Ctr Reprod & Genet Hlth, London, England
[5] Univ Hosp Ghent, Obstet & Gynaecol, Ghent, Belgium
[6] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic, Australia
[7] Univ Med Ctr, Dept Reprod Med & Gynecol, Utrecht, Netherlands
[8] Kings Coll London, Fac Life Sci & Med, Div Womens Hlth, London, England
关键词
OFFICE HYSTEROSCOPY; ENDOMETRIAL INJURY; UTERINE CAVITY; IVF CYCLE; INFERTILITY; IMPLANTATION; INSEMINATION; TECHNOLOGY; PREVALENCE; FERTILITY;
D O I
10.1002/14651858.CD012856.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Screening hysteroscopy in infertile women with unexplained infertility, or prior to intrauterine insemination (IUI) or in vitro fertilisation (IVF) may reveal intrauterine pathology that may not be detected by routine transvaginal ultrasound. Hysteroscopy, whether purely diagnostic or operative may improve reproductive outcomes. Objectives To assess the effectiveness and safety of screening hysteroscopy in subfertile women undergoing evaluation for infertility, and subfertile women undergoing IUI or IVF. Search methods We searched the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL CRSO, MEDLINE, Embase, Clinical-Trials. gov,and the World Health Organization International Clinical Trials Registry Platform (September 2018). We searched reference lists of relevant articles and handsearched relevant conference proceedings. Selection criteria Randomised controlled trials comparing screening hysteroscopy versus no intervention in subfertile women wishing to conceive spontaneously, or before undergoing IUI or IVF. Data collection and analysis We independently screened studies, extracted data, and assessed the risk of bias. The primary outcomes were live birth rate and complications following hysteroscopy. We analysed data using risk ratio (RR) and a fixed-effect model. We assessed the quality of the evidence by using GRADE criteria. Main results We retrieved 11 studies. We included one trial that evaluated screening hysteroscopy versus no hysteroscopy, in women with unexplained subfertility, who were trying to conceive spontaneously. We are uncertain whether ongoing pregnancy rate improves following a screening hysteroscopy in women with at least two years of unexplained subfertility (RR 4.30, 95% CI 2.29 to 8.07; 1 RCT; participants = 200; very low-quality evidence). For a typical clinic with a 10% ongoing pregnancy rate without hysteroscopy, performing a screening hysteroscopy would be expected to result in ongoing pregnancy rates between 23% and 81%. The included study reported no adverse events in either treatment arm. We are uncertain whether clinical pregnancy rate is improved (RR 3.80, 95% CI 2.31 to 6.24; 1 RCT; participants = 200; very low-quality evidence), or miscarriage rate increases (RR 2.80, 95% CI 1.05 to 7.48; 1 RCT; participants = 200; very low-quality evidence), following screening hysteroscopy in women with at least two years of unexplained subfertility. We included ten trials that included 1836 women who had a screening hysteroscopy and 1914 women who had no hysteroscopy prior to IVF. Main limitations in the quality of evidence were inadequate reporting of study methods and higher statistical heterogeneity. Eight of the ten trials had unclear risk of bias for allocation concealment. Performing a screening hysteroscopy before IVF may increase live birth rate (RR 1.26, 95% CI 1.11 to 1.43; 6 RCTs; participants = 2745; I (2) = 69 %; low-quality evidence). For a typical clinic with a 22% live birth rate, performing a screening hysteroscopy would be expected to result in live birth rates between 25% and 32%. However, sensitivity analysis done by pooling results from trials at low risk of bias showed no increase in live birth rate following a screening hysteroscopy (RR 0.99, 95% CI 0.82 to 1.18; 2 RCTs; participants = 1452; I (2) = 0%). Only four trials reported complications following hysteroscopy; of these, three trials recorded no events in either group. We are uncertain whether a screening hysteroscopy is associated with higher adverse events (Peto odds ratio 7.47, 95% CI 0.15 to 376.42; 4 RCTs; participants = 1872; I (2) = not applicable; very low-quality evidence). Performing a screening hysteroscopy before IVF may increase clinical pregnancy rate (RR 1.32, 95% CI 1.20 to 1.45; 10 RCTs; participants = 3750; I (2) = 49%; low-quality evidence). For a typical clinic with a 28% clinical pregnancy rate, performing a screening hysteroscopy would be expected to result in clinical pregnancy rates between 33% and 40%. There may be little or no difference in miscarriage rate following screening hysteroscopy (RR 1.01, 95% CI 0.67 to 1.50; 3 RCTs; participants = 1669; I (2) = 0%; low-quality evidence). We found no trials that compared a screening hysteroscopy versus no hysteroscopy before IUI. Authors ' conclusions At present, there is no high-quality evidence to support the routine use of hysteroscopy as a screening tool in the general population of subfertile women with a normal ultrasound or hysterosalpingogram in the basic fertility work-up for improving reproductive success rates. In women undergoing IVF, low-quality evidence, including all of the studies reporting these outcomes, suggests that performing a screening hysteroscopy before IVF may increase live birth and clinical pregnancy rates. However, pooled results from the only two trials with a low risk of bias did not show a benefit of screening hysteroscopy before IVF. Since the studies showing an effect are those with unclear allocation concealment, we are uncertain whether a routine screening hysteroscopy increases live birth and clinical pregnancy, be it for all women, or those
引用
收藏
页数:68
相关论文
共 50 条
  • [41] Long-acting FSH versus daily FSH for women undergoing assisted reproduction
    Pouwer, Annefloor W.
    Farquhar, Cindy
    Kremer, Jan A. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (07):
  • [42] Improving analysis of the vaginal microbiota of women undergoing assisted reproduction using nanopore sequencing
    Luth, Theresa
    Graspeuntner, Simon
    Neumann, Kay
    Kirchhoff, Laura
    Masuch, Antonia
    Schaake, Susen
    Lupatsii, Mariia
    Tse, Ronnie
    Griesinger, Georg
    Trinh, Joanne
    Rupp, Jan
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2022, 39 (11) : 2659 - 2667
  • [43] Quality of life assessment in women undergoing assisted reproduction. A study of FertiQol and HADS
    Figueras-Puigderrajols, N.
    Ballesteros, A.
    Guerra, D.
    HUMAN REPRODUCTION, 2021, 36 : 354 - 354
  • [44] Risk of pelvic inflammatory disease in subfertile women undergoing uterine instrumentation
    Guaschino, S
    Ricci, G
    De Seta, F
    HUMAN REPRODUCTION, 2005, : 408 - 410
  • [45] Serum and follicular fluid organochlorine concentrations among women undergoing assisted reproduction technologies
    Meeker, John D.
    Missmer, Stacey A.
    Altshul, Larisa
    Vitonis, Allison F.
    Ryan, Louise
    Cramer, Daniel W.
    Hauser, Russ
    ENVIRONMENTAL HEALTH, 2009, 8 : 32
  • [46] Cumulative pregnancy and live birth rates in women with antiphospholipid antibodies undergoing assisted reproduction
    Eldar-Geva, T
    Wood, C
    Lolatgis, N
    Rombauts, L
    Kovacs, G
    Fuscaldo, J
    Trounson, AO
    HUMAN REPRODUCTION, 1999, 14 (06) : 1461 - 1466
  • [47] Long-acting FSH versus daily FSH for women undergoing assisted reproduction
    Pouwer, A. W.
    Farquhar, C.
    Kremer, J. A. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (06):
  • [48] Serum and follicular fluid organochlorine concentrations among women undergoing assisted reproduction technologies
    John D Meeker
    Stacey A Missmer
    Larisa Altshul
    Allison F Vitonis
    Louise Ryan
    Daniel W Cramer
    Russ Hauser
    Environmental Health, 8
  • [49] Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction
    Alvarez, Claudio
    Marti-Bonmati, Luis
    Novella-Maestre, Edurne
    Sanz, Roberto
    Gomez, Raul
    Fernandez-Sanchez, Manuel
    Simon, Carlos
    Pellicer, Antonio
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08): : 2931 - 2937
  • [50] In vitro maturation in sub fertile women with polycystic ovarian syndrome undergoing assisted reproduction
    Siristatidis, Charalambos S.
    Maheshwari, Abha
    Bhattacharya, Siladitya
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):